Pancreatic cancer — frontier options in Arizona

30 open options

TRIALPHASE3RECRUITING
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Setidegrasib · Oxaliplatin · Leucovorin — 48 sites
EXPANDED ACCESSAVAILABLE
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
daraxonrasib — 257 sites
TRIALPHASE2RECRUITING
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Biospecimen Collection · Computed Tomography · Magnetic Resonance Imaging — 454 sites
TRIALPHASE3RECRUITING
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Atebimetinib · GnP · mGnP — 38 sites
TRIALPHASE2RECRUITING
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Pemigatinib · Computed Tomography (CT) · Magnetic Resonance Imaging — 109 sites
TRIALPHASE3RECRUITING
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RYZ101 · Everolimus · Sunitinib — 54 sites
TRIALPHASE3RECRUITING
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
daraxonrasib — 66 sites
TRIALPHASE1RECRUITING
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
LY4170156 · bevacizumab · carboplatin — 23 sites
TRIALPHASE2 / PHASE3RECRUITING
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
ponsegromab · placebo — 220 sites
TRIALPHASE1RECRUITING
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
INCB161734 · Cetuximab · Retifanlimab — 34 sites
TRIALNARECRUITING
Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) — 15 sites
TRIALPHASE2RECRUITING
A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
nuzefatide pevedotin (BT5528) — 6 sites
TRIALPHASE1 / PHASE2RECRUITING
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
RMC-6236 · mFOLFOX6 regimen · bevacizumab — 32 sites
TRIALPHASE3RECRUITING
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Biospecimen Collection · Computed Tomography · Fluorouracil — 274 sites
TRIALPHASE2RECRUITING
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
TCMCB07 · Placebo — 26 sites
TRIALPHASE3RECRUITING
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
INCB161734 · Placebo · Investigator's choice of chemotherapy — 219 sites
TRIALPHASE1 / PHASE2RECRUITING
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
ART0380 · Gemcitabine · Irinotecan — 82 sites
TRIALPHASE1RECRUITING
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
PF-08046050 · bevacizumab · 5-Fluorouracil (5-FU) — 48 sites
TRIALPHASE1RECRUITING
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
SHY-ONC6 — 4 sites
TRIALPHASE3RECRUITING
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Biospecimen Collection · Distal Pancreatectomy · Lanreotide — 118 sites
TRIALPHASE2RECRUITING
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Capecitabine · Temozolomide — 448 sites
TRIALPHASE3RECRUITING
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Zoldonrasib · Placebo · Oxaliplatin — 6 sites
TRIALPHASE3RECRUITING
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Paltusotine · Placebo — 67 sites
TRIALPHASE2RECRUITING
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
Acoustic Cluster Therapy · Modified FOLFIRINOX — 10 sites
TRIALPHASE1RECRUITING
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA-313 · Olaparib — 18 sites
TRIALPHASE3RECRUITING
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Biopsy Procedure · Biospecimen Collection · Capecitabine — 333 sites
TRIALPHASE3RECRUITING
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
daraxonrasib · gemcitabine · nab-paclitaxel — 25 sites
TRIALPHASE2RECRUITING
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Relacorilant · Nab-paclitaxel · Gemcitabine — 16 sites
TRIALEARLY_PHASE1NOT_YET_RECRUITING
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
GLP1-RA (semaglutide) — 1 site
TRIALPHASE1RECRUITING
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
MRTX1719 — 25 sites

Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.